Adlai Nortye (ANL) Stock Overview
A clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ANL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Adlai Nortye Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.77 |
| 52 Week High | US$17.25 |
| 52 Week Low | US$0.88 |
| Beta | 1.11 |
| 1 Month Change | 5.28% |
| 3 Month Change | -10.25% |
| 1 Year Change | 586.60% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -28.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| ANL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.6% | 2.3% | 0.8% |
| 1Y | 586.6% | 42.3% | 20.2% |
Return vs Industry: ANL exceeded the US Biotechs industry which returned 42.3% over the past year.
Return vs Market: ANL exceeded the US Market which returned 20.2% over the past year.
Price Volatility
| ANL volatility | |
|---|---|
| ANL Average Weekly Movement | 17.6% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ANL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ANL's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 109 | Carsten Lu | www.adlainortye.com |
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed to deliver potent anti-tumor activity with an improved therapeutic window; and AN8025, a tri-specific antibody fusion protein which is in phase Ia clinical trial to treat advanced tumors.
Adlai Nortye Ltd. Fundamentals Summary
| ANL fundamental statistics | |
|---|---|
| Market cap | US$430.80m |
| Earnings (TTM) | -US$35.53m |
| Revenue (TTM) | US$5.00m |
Is ANL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANL income statement (TTM) | |
|---|---|
| Revenue | US$5.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$5.00m |
| Other Expenses | US$40.53m |
| Earnings | -US$35.53m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 100.00% |
| Net Profit Margin | -710.56% |
| Debt/Equity Ratio | -295.4% |
How did ANL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/08 01:32 |
| End of Day Share Price | 2026/07/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Adlai Nortye Ltd. is covered by 6 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Joseph Pantginis | H.C. Wainwright & Co. |
| Boris Peaker | JonesTrading Institutional Services, LLC |